3 papers
stat.ME2018
Estimating the treatment effect in a subgroup defined by an early post-baseline biomarker measurement in randomized clinical trials with time-to-event endpoint
Björn Bornkamp, Georgina Bermann
Biomarker measurements can be relatively easy and quick to obtain and they are useful to investigate whether a compound works as intended on a mechanistic, pharmacological level. I…
stat.ME2017
Bayesian optimal designs for dose-response curves with common parameters
Kirsten Schorning, Maria Konstantinou
The issue of determining not only an adequate dose but also a dosing frequency of a drug arises frequently in Phase II clinical trials. This results in the comparison of models whi…
math.ST2016
Optimal designs for dose response curves with common parameters
Chrystel Feller, Kirsten Schorning, Holger Dette +2
A common problem in Phase II clinical trials is the comparison of dose response curves corresponding to different treatment groups. If the effect of the dose level is described by…